The article details the materials that will be used in a clinical trial - ECG AI-Guided Screening for Low Ejection Fraction (EAGLE): Rationale and design of a pragmatic cluster randomized trial [1]. It includes a clinician-facing action recommendation report that will translate an artificial intelligence algorithm to routine practice and an alert when a positive screening result is found. This report was developed using a user-centered approach via an iterative process with input from multiple physician groups. Such data can be reused and adapted to translate other artificial intelligence algorithms. This article also includes data collection forms we developed for the clinical trial aiming to evaluate the artificial intelligence algorithm. Such materials can be adapted for other clinical trials.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6906686 | PMC |
http://dx.doi.org/10.1016/j.dib.2019.104894 | DOI Listing |
Postgrad Med J
January 2025
Proof of Concept Center, Eastern Hepatobiliary Surgery Hospital, Third Affiliated Hospital, Second Military Medical University, Naval Medical University, No. 255, Yangpu District, Shanghai, 200433, China.
Objectives: The objective was to investigate the role of double extraction in reducing data errors in evidence synthesis for pharmaceutical and non-pharmaceutical interventions.
Design: Crossover randomized controlled trial (RCT).
Setting: University and hospital with teaching programs in evidence-based medicine.
EClinicalMedicine
December 2024
Department of Neurology, Brain Research Institute, Niigata University, Niigata, Japan.
Background: Therapeutic advancements for the polyglutamine diseases, particularly spinocerebellar degeneration, are eagerly awaited. We evaluated the safety, tolerability, and therapeutic effects of L-arginine, which inhibits the conformational change and aggregation of polyglutamine proteins, in patients with spinocerebellar ataxia type 6 (SCA6).
Methods: A multicenter, randomized, double-blind, placebo-controlled phase 2 trial (clinical trial ID: AJA030-002, registration number: jRCT2031200135) was performed on 40 genetically confirmed SCA6 patients enrolled between September 1, 2020, and September 30, 2021.
Front Physiol
December 2024
Department of Sport and Exercise Science, Paris Lodron University Salzburg, Salzburg, Austria.
Introduction: Our recent meta-analyses have demonstrated that high-intensity interval training (HIIT) causes a range of mean changes in various measures and predictors of endurance and sprint performance in athletes. Here, we extend the analyses to relationships between mean changes of these measures and consider implications for understanding and improving HIIT that were not apparent in the previous analyses.
Methods: The data were mean changes from HIIT with highly trained endurance and elite other (mainly team sport) athletes in studies where two or more measures or predictors of performance were available.
Clin Interv Aging
December 2024
Department of Anesthesiology, The Affiliated Hospital of Yangzhou University, Yangzhou, 225012, People's Republic of China.
Purpose: Low density of electroencephalogram alpha band power was reported to be associated with perioperative cognitive dysfunction. Few studies have conducted to explore the effects of remimazolam on intraoperative frontal alpha band power spectrum density in older adults. Here, we aimed to explore the impact of remimazolam on intraoperative frontal brain wave alpha band activity and postoperative cognitive function in older adults undergoing lower extremity fractures surgeries.
View Article and Find Full Text PDFFront Neurol
December 2024
Department of Neurology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, China.
Background: Low-density lipoprotein cholesterol (LDL-C) has been determined as an established risk factor for acute ischemic stroke (AIS). Despite the recommendation for in-hospital initiation of high-intensity statin therapy in AIS patients, achieving the desired target LDL-C levels remains challenging. Evolocumab, a highly effective and quickly acting agent for reducing LDL-C levels, has yet to undergo extensively exploration in the acute phase of AIS.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!